Novartis AG (NOVN.SW): analysis and signal as of September 7, 2026
In short
The signal is moderate with a vote of 2/3 and no numerical score assigned. The thesis rests on the defensive quality of the stock, whose relative valuation remains attractive given the slowdown in organic growth.
- Current signal
- moderate (vote 2/3)
- Deterministic score
- +5.5 → signal expected by the scale : strong (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : positive
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| favors robust fundamental health (high Piotroski F-Score) | +1.5 |
| favors high gross profitability (gross profit / assets), a robust predictor of returns | +1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
Novartis presents a defensive quality profile, supported by a broad competitive advantage, a high return on invested capital, and recurring share buybacks. The EXPANSION-type macroeconomic regime underpins the healthcare sector. Organic growth for the second half of 2026 stands at +1 % at constant currency and the 2026 guidance anticipates a decline in core operating profit in the low single digit, which limits the immediate upside catalyst. The stock trades at +10.2 % above its 200-session moving average, while the analyst consensus displays a target of 132.91 CHF, or only +2.4 % above the current price.
Bull case
The PER stands at 18.79, down versus the 5-year average of 23.72. The dividend yield reaches 3.16 % and a new buyback programme was launched on 14/03/2026. The short interest remains low at 0.26 % of the free float. The macro regime favours the healthcare sector and the 19.2 % decline in volatility reinforces the defensive dimension.
Bear case
Organic growth for the second half of 2026 is limited to +1 % at constant currency versus +8 % in 2025. The 2026 guidance incorporates a decline in core operating profit in the low single digit. US generic erosion affects priority brands, the Cboe risk regime reflects a certain complacency with a volatility slope of -32 %, the appeal on the Entresto patent remains ongoing, and the weakness in the overnight at -7.3 bp per day contradicts the bullish reading.
Scenarios
The bullish scenario, assigned a probability of 35 %, targets 155 CHF, or +19 %. The central scenario, at 45 %, anticipates 130 CHF, close to the current price. The bearish scenario, at 20 %, initially provided for a maximum loss of -10.6 % with a close below the 200-session moving average at 117 CHF, but this numerical threshold falls under the register of recommendations and is not published here.
Risks
US generic erosion on priority brands, the slowdown in organic growth in the second half of 2026, and the guided decline in core operating profit constitute the main points of vigilance. The holding of the 200-session moving average represents a qualitative watch zone, the appeal on the Entresto patent remains an external factor to be integrated, and the weakness in the overnight signals a degraded short-term dynamic.
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| moderate (2/3) | unchanged Personal analysis, not advice. | |
| moderate (3/3) | unchanged (first verdict recorded on this stock, no new quantified data prior to 02/09/2026 justifies an immediate announcement) Personal analysis, not advice. |
Frequently asked questions
What is the current signal on Novartis and how is it constructed?
The quality signal is moderate with a vote of 2/3 and no numerical score is assigned. It rests on the defensive thesis of the stock and the weighting of bullish and bearish arguments. The slowdown in organic growth in H2 2026 to +1 % at constant currency and the guided decline in core operating profit explain the cautious nature of the verdict.
Why does the valuation remain a point of strength?
The PER stands at 18.79 versus a 5-year average of 23.72, signalling a relative discount. The dividend yield reaches 3.16 % and a new buyback programme was launched on 14/03/2026. These elements provide structural support to the thesis.
What factors temper the optimism?
Organic growth in H2 2026 falls to +1 % at constant currency versus +8 % in 2025. The 2026 guidance includes a decline in core operating profit in the low single digit. US generic erosion, the appeal on Entresto, and the weakness in the overnight at -7.3 bp per day complete the bearish picture.
What should be taken away from the analyst consensus?
The consensus displays a target of 132.91 CHF, or +2.4 % above the current price, reflecting a mixed view. This modest target supports the cautious reading of the moderate verdict, particularly as the stock already trades +10.2 % above its 200-session moving average.
What are the probabilities of the scenarios envisaged?
The bullish scenario is assessed at 35 % with a target of 155 CHF, or +19 %. The central scenario, at 45 %, anticipates 130 CHF close to the price. The bearish scenario, at 20 %, evokes a maximum loss of -10.6 % linked to a close below the 200-session moving average.
Sources
No official filing is attached to this stock in the database to date. The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 7, 2026; this page was completed on September 7, 2026 at 07:23 (UTC).
- Interests: no position in the stock analysed (NOVN.SW) is recorded in the data consulted on (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: Amgen Inc. (AMGN)
- All analysed stocks
- Public methodology